Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07024693Phase 2Recruiting

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Role: lead

NCT06874010Phase 1Recruiting

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

Role: lead

NCT06772870Phase 1Not Yet Recruiting

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Role: lead

NCT05573698Phase 1Completed

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

Role: lead

NCT05285540Phase 1Completed

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Role: lead

All 5 trials loaded